UroGen Pharma Ltd.
ZUSDURI
recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)
Resolved
102days ago
FDA decision · Mar 27, 2026
What's at stake
The FDA's approval decision on ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) is due Mar 27, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 16h ago
“the FDA has set a PDUFA action date of March 27, 2026”